Találati lista | Tudóstér

001-es BibID:	BIBFORM063657
Első szerző:	Hortobágyi Tibor (patológus)
Cím:	Meningioma recurrence / Tibor Hortobágyi, János Bencze, Gréta Varkoly, Mahan C. Kouhsari, Álmos Klekner
Dátum:	2016
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Open Medicine. - 11 : 1 (2016), p. 168-173. -
További szerzők:	Bencze János (1991-) (orvos) Varkoly Gréta (1990-) (orvos) Kouhsari, Mahan C. Klekner Álmos (1970-) (idegsebész)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM070808
Első szerző:	Murnyák Balázs (molekuláris biológus, genetikus)
Cím:	Genomic signature of PARP1 in glioblastoma molecular subtypes / Balázs Murnyák, Mahan C. Kouhsari, Rotem Hershkovitch, Álmos Klekner, Tibor Hortobágyi
Dátum:	2017
Megjegyzések:	Introduction: Glioblastoma (GBM) is an aggressive and frequent primary brain tumour in adults. Overexpression of PARP1 has been reported in various cancers, including GBM. Although PARP1 inhibition is a promising therapeutic target, no comprehensive analysis has addressed PARP1's expression regarding molecularheterogeneity in GBM.Aim of the study: The main objective of our study was to evaluate PARP1's associations with GBM lineage specific markers, and its transcriptomic subtypes.Material and methods: PARP1's somatic mutations, copy number alterations (CNAs), and mRNA expression, as well as survival data were collected from the ♭Glioblastoma Multiforme' TCGA dataset. A bioinformatic analysis was conducted a to evaluate PARP1's genetic signature, and prognostic role in GBM.Results: Our study revealed that PARP1 CNA gain and high mRNA expression level is a characteristic of Proneural (PN) and Classical (CL) GBM subtypes. Increased PARP1 levels exhibited an inverse correlation with patient survival (p<0.005) in the CL subgroup. ATRX (p=0.006), and TP53 (p=0.015) mutations were associated with increased PARP1 mRNA expression.Conclusions: Our study supports the therapeutic role of PARP inhibitors in GBM with the caveat that molecular heterogeneity needs to be taken into account.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok előadáskivonat Bioinformatics Oncogenetics PARP1 GBM
Megjelenés:	13th Warsaw International Medical Congress : Abstract Book / The Students' Scientific Association of the Medical University of Warsaw. - Warsaw : Medical University of Warsaw, 2017. - 242. p. -
További szerzők:	Kouhsari, Mahan C. Hershkovitch, Rotem Klekner Álmos (1970-) (idegsebész) Hortobágyi Tibor (1965-) (patológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM068928
Első szerző:	Murnyák Balázs (molekuláris biológus, genetikus)
Cím:	PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma / Balázs Murnyák, Mahan C. Kouhsari, Rotem Hershkovitch, Bernadette Kálmán, György Marko-Varga, Álmos Klekner, Tibor Hortobágyi
Dátum:	2017
ISSN:	1949-2553
Megjegyzések:	Overexpression of PARP1 exists in various cancers, including glioblastoma (GBM). Although PARP1 inhibition is a promising therapeutic target, no comprehensive study has addressed PARP1's expression characteristics and prognostic role regarding molecular heterogeneity in astrocytomas including GBM. Our aim was to evaluate PARP1's associations with survival, WHO grade, lineage specific markers, and GBM transcriptomic subtypes. We collected genomic and clinical data from the latest glioma datasets of The Cancer Genome Atlas and performed PARP1, ATRX, IDH1, and p53 immunohistochemistry on GBM tissue samples. We demonstrated that PARP1 gain and increased mRNA expression are characteristics of high-grade astrocytomas, particularly of Proneural and Classical GBM subtypes. Additionally, higher PARP1 levels exhibited an inverse correlation with patient survival (p<0.005) in the Classical subgroup. ATRX (p=0.006), and TP53 (p=0.015) mutations were associated with increased PARP1 expression and PARP1 protein level correlated with ATRX loss and p53 overexpression. Furthermore, higher PARP1 expression together with wildtype TP53 indicated shorter survival (p=0.039). Therefore, due to subtype specificity, PARP1 expression level and TP53 mutation status are reliable marker candidates to distinguish Proneural and Classical subtypes, with prognostic and therapeutic implications in GBM.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban glioma glioblastoma p53 PARP1
Megjelenés:	Oncotarget. - 8 : 28 (2017), p. 46348-46362. -
További szerzők:	Kouhsari, Mahan C. Hershkovitch, Rotem Kálmán Bernadette Marko-Varga György Klekner Álmos (1970-) (idegsebész) Hortobágyi Tibor (1965-) (patológus)
Pályázati támogatás:	ÚNKP-16-3 Egyéb KTIA_13_NAP-A-II/7 Egyéb KTIA_13_NAP-A-V/3 Egyéb AGR_PIAC_13-1-2013-0008 Egyéb GINOP-2.3.2-15-2016-00043 GINOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM077127
Első szerző:	Virga József
Cím:	Extracellular matrix differences in glioblastoma patients with different prognoses / Virga J., Szivos L., Hortobágyi T., Kouhsari M. C., Zahuczky G., Steiner L., Tóth J., Reményi-Puskár J., Bognár L., Klekner Á.
Dátum:	2019
Megjegyzések:	Glioblastoma is the most common malignant central nervous system tumor. Patient outcome remains poor despite the development of therapy and increased understanding of the disease in the past decades. Glioma cells invade the peritumoral brain, which results in inevitable tumor recurrence. Previous studies have demonstrated that the extracellular matrix (ECM) is altered in gliomas and serves a major role in glioma invasion. The present study focuses on differences in the ECM composition of tumors in patients with poor and improved prognosis. The mRNA and protein expression of 16 invasion?associated ECM molecules was determined using reverse trascription?quantitiative polymerase chain reaction and immunohistochemistry, respectively. Clinical factors of patients with different prognoses was also analyzed. It was determined that age and postoperative Karnofsky performance score were associated with patient survival. Furthermore, Fms?related tyrosine kinase 4/vascular endothelial growth factor receptor 3 (FLT4/VEGFR3), murine double minute 2 (MDM2) and matrix metallopeptidase 2 (MMP2) mRNA levels were significantly different between the two prognostic groups. Additionally, brevican, cluster of differentiation 44, hyaluronan mediated motility receptor, integrin??V and ??1, and MDM2 protein expression were indicated to be significantly different in immunohistochemistry slides. Using the expression profile, including the invasion spectrum of the samples, it was possible to identify the prognostic group of the sample with high efficacy, particularly in cases with poor prognosis. In conclusion, it was determined that ECM components exhibit different expression levels in tumors with different prognoses and thus the invasion spectrum can be used as a prognostic factor in glioblastoma.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Oncology letters. - 17 : 1 (2019), p. 797-806. -
További szerzők:	Szivos László (1993-) (idegsebész) Hortobágyi Tibor (1965-) (patológus) Kouhsari, Mahan C. Zahuczky Gábor (1975-) (molekuláris biológus, biokémikus, vegyész) Steiner László Tóth Judit (1958-) (onkológus szakorvos) Reményi-Puskár Judit Bognár László (1958-) (idegsebész, gyermekidegsebész) Klekner Álmos (1970-) (idegsebész)
Pályázati támogatás:	2017-1.2.1-NKP-2017-00002 Egyéb ÚNKP-17-3-I and ÚNKP-17-2-I ÚNKP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: